Arvinas Sale Purchase Of Stock Over Time
| ARVN Stock | USD 19.00 0.08 0.42% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arvinas Performance and Arvinas Correlation. Arvinas |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arvinas. If investors know Arvinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arvinas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.79) | Revenue Per Share 2.327 | Quarterly Revenue Growth 1.96 | Return On Assets (0.20) | Return On Equity (0.59) |
The market value of Arvinas is measured differently than its book value, which is the value of Arvinas that is recorded on the company's balance sheet. Investors also form their own opinion of Arvinas' value that differs from its market value or its book value, called intrinsic value, which is Arvinas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arvinas' market value can be influenced by many factors that don't directly affect Arvinas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arvinas' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arvinas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arvinas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Sale Purchase Of Stock Analysis
Compare Arvinas and related stocks such as C4 Therapeutics, Monte Rosa Therapeutics, and Nurix Therapeutics Sale Purchase Of Stock Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CCCC | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (194 K) | 2 M | 777 K | (110 K) | (104.5 K) |
| GLUE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (440 K) | 377.6 M | 20.8 M | 24 M | 22.8 M |
| NRIX | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | 529 K | (16 K) | (7 K) | (1000) | 117.2 M | 117.2 M | 134.8 M | 141.5 M |
| RLAY | 394.3 M | 394.3 M | 394.3 M | 394.3 M | 394.3 M | 394.3 M | 394.3 M | 394.3 M | 394.3 M | 5.6 M | 429 M | 5.9 M | 1.7 M | 1.5 M | 1.4 M |
| STOK | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 116 M | 152.2 M | 108.3 M | 1.3 M | 1.1 M | 957.6 K | 909.7 K |
| PLRX | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 87.3 M | 48.1 M | 213.2 M | 2.5 M | 215.6 M | 248 M | 260.4 M |
| BDTX | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 52.3 M | 129.5 M | 214.9 M | 729 K | 177 K | 159.3 K | 151.3 K |
| STTK | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 213.2 M | 1.9 M | 171 K | (53 K) | (50.4 K) |
| KYMR | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 276.3 M | 8 M | 4.3 M | 3.9 M | 3.7 M |
| RARE | 189.3 M | 189.3 M | 189.3 M | 189.3 M | 189.3 M | 467.6 M | 87.3 M | 141.2 M | 298.8 M | 340.2 M | 524.8 M | 40.1 M | 10.8 M | 9.7 M | 9.2 M |
| CRNX | (5 K) | (5 K) | (5 K) | (5 K) | (5 K) | (5 K) | (5 K) | 12 M | 170.2 M | (59 K) | 114.6 M | 0.0 | 0.0 | 0.0 | 0.0 |
| RVMD | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 60.8 M | (45 K) | 832 K | 1.9 M | 1.9 M | 3.3 M | 3.2 M |
| KURA | (4.2 K) | (4.2 K) | (4.8 K) | (6.6 K) | 1000 | 97.9 M | 53.9 M | 53.9 M | 132.2 M | 108.2 M | 459.3 M | 29.1 M | 29.1 M | 33.5 M | 31.8 M |
| IPSC | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 223.9 M | 27.2 M | 24.4 M | 23.2 M |
Arvinas and related stocks such as C4 Therapeutics, Monte Rosa Therapeutics, and Nurix Therapeutics Sale Purchase Of Stock description
My Equities
My Current Equities and Potential Positions
| Arvinas | ARVN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Connecticut; U.S.A |
| Exchange | NASDAQ Exchange |
USD 19.0
Check out Arvinas Performance and Arvinas Correlation. To learn how to invest in Arvinas Stock, please use our How to Invest in Arvinas guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Arvinas technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.